Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA 2416, a Lipid Nanoparticle Encapsulated mRNA Encoding Human OX40L, for Intratumoral Injection to Patients With Advanced Malignancies

Trial Profile

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA 2416, a Lipid Nanoparticle Encapsulated mRNA Encoding Human OX40L, for Intratumoral Injection to Patients With Advanced Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Jan 2019

At a glance

  • Drugs MRNA-2416 (Primary)
  • Indications Carcinoma; Lymphoma; Ovarian cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Moderna Therapeutics
  • Most Recent Events

    • 08 Jan 2019 According to a Moderna Therapeutics media release, Initial data were presented at the Annual Meeting of the Society for Immunotherapy of Cancer in November 2018.
    • 08 Jan 2019 According to a Moderna Therapeutics media release, based on clinical observations from two advanced ovarian carcinoma patients of the study, the company has submitted an IND amendment to the U.S. FDA and to the studys clinical research sites to commence a Phase 2 cohort of mRNA-2416 as a monotherapy in advanced ovarian carcinoma within current Phase 1 study. 28 patients have been dosed in the Phase 1 trial.
    • 21 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top